Administration of protein C concentrates in patients without congenital deficit: a systematic review of the literature

Abstract

ABSTRACT

Protein C zymogen in severe sepsis: a double-blinded, placebo-controlled, randomized study

“…Our study confirmed previous findings [11,12,14,16,29] that the use of protein C zymogen is not associated with an increased risk for thrombosis or bleeding. As a matter of fact, incidence of bleeding complications in our study was lower than reported in other case series [30].…”

“…Overall, over 340 patients with non-congenital protein C deficits received protein C zymogen and had the results published [16]. No bleeding complications related to the study drug were reported, and most studies underlined normalization of inflammatory markers and of coagulation abnormalities.…”

“…Several case reports and case series [12,14,15] recently suggested that protein C zymogen is safe in adult patients and is associated with a lower-than-predicted mortality in severe sepsis and septic shock settings [16].…”

“…Evidence has accumulated on the relevance of the PC pathway in modulating overwhelming inflammation and preventing coagulation derangements, two key mediators of organ damage in sepsis [17,18]. At the clinical level, protein C zymogen has been administered to more than 340 patients with congenital protein C deficits without any bleeding or allergic complications, and with improvements in coagulation abnormalities [16]. Recent reports suggest that its use is expanding in other settings [19][20][21].…”